Associate Professor of Pharmacology and Cancer Biology
Appointments and Affiliations
- Associate Professor of Pharmacology and Cancer Biology
- Associate Professor of Cell Biology
- Core Faculty in Innovation & Entrepreneurship
- Member of the Duke Cancer Institute
Contact Information
- Email Address: kris.wood@duke.edu
- Websites:
Education
- B.S. University of Kentucky, 2002
- Ph.D. Massachusetts Institute of Technology, 2007
Courses Taught
- CMB 710B: Cell & Molecular Biology Module II
- CMB 710E: Cell & Molecular Biology Module V
- MOLCAN 818: Molecular Mechanisms of Oncogenesis
- PHARM 393: Research Independent Study
- PHARM 394: Research Independent Study
- PHARM 493: Research Independent Study
- PHARM 494: Research Independent Study
- PHARM 495: Research Independent Study
- PHARM 818: Molecular Mechanisms of Oncogenesis
- UPGEN 778A: University Program in Genetics and Genomics Biological Solutions Module I
In the News
- Locking Leukemia's Cellular Escape Hatch (Jun 7, 2022 | Pratt)
- Cancer Repair Mechanism Could Be Potential Drug Target (Mar 31, 2022 | Duke Hea…
- Cancer Therapy Using Genetic Targeting and Gel Delivery Shows Promise (Sep 16, …
- From Innovation to Impact (Oct 3, 2018 | Duke Med Alumni News)
- Faculty Startup Sold to Belgian Pharma for $30 Million (Apr 9, 2018)
- Why Do Perfectly Good Cancer Treatments Suddenly Stop Working? (Oct 25, 2017 | …
- The Challenges of Combating Cancer Drug Resistance (Nov 19, 2015 | Duke Researc…
- Researchers Map Paths to Cancer Drug Resistance (Jan 5, 2015)
Representative Publications
- Goodwin, Craig M., Andrew M. Waters, Jennifer E. Klomp, Sehrish Javaid, Kirsten L. Bryant, Clint A. Stalnecker, Kristina Drizyte-Miller, et al. “Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-mutant Pancreatic Cancer.” Cancer Res, November 8, 2022. https://doi.org/10.1158/0008-5472.CAN-22-0391.
- Wood, Kris C., and J Silvio Gutkind. “Challenges and Emerging Opportunities for Targeting mTOR in Cancer.” Cancer Res 82, no. 21 (November 2, 2022): 3884–87. https://doi.org/10.1158/0008-5472.CAN-22-0602.
- Lidsky, Michael E., Zechen Wang, Min Lu, Annie Liu, S David Hsu, Shannon J. McCall, Zhecheng Sheng, et al. “Leveraging patient derived models of FGFR2 fusion positive intrahepatic cholangiocarcinoma to identify synergistic therapies.” Npj Precis Oncol 6, no. 1 (October 23, 2022): 75. https://doi.org/10.1038/s41698-022-00320-5.
- Kishton, Rigel J., Shashank J. Patel, Amy E. Decker, Suman K. Vodnala, Maggie Cam, Tori N. Yamamoto, Yogin Patel, et al. “Cancer genes disfavoring T cell immunity identified via integrated systems approach.” Cell Rep 40, no. 5 (August 2, 2022): 111153. https://doi.org/10.1016/j.celrep.2022.111153.
- Lin, Kevin H., Justine C. Rutter, Abigail Xie, Shane T. Killarney, Camille Vaganay, Chaima Benaksas, Frank Ling, et al. “P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia.” Nat Cancer 3, no. 7 (July 2022): 837–51. https://doi.org/10.1038/s43018-022-00394-x.